BOTULAX®

About BOTULAX® — South Korea’s Leading Botulinum Toxin Type A

Hugel Inc., the BOTULAX® manufacturer, was founded in Seoul in 2001 and has since built a portfolio around neurotoxins, hyaluronic acid dermal fillers, and cosmeceutical lines. BOTULAX® is produced from highly purified Clostridium botulinum toxin using Size Exclusion High Performance Liquid Chromatography, with Hugel reporting purity in excess of 99%. Under International Nonproprietary Name conventions, the active substance is letibotulinumtoxinA, the same underlying toxin Hugel has since brought to the US market as LETYBO® under the specific designation letibotulinumtoxinA-wlbg.[4]

The formulation is stabilized with human serum albumin and sodium chloride, which help the toxin complex hold together through lyophilization and refrigerated storage. Dual compliance under MFDS and CE quality frameworks has been central to the product’s international reach across medical aesthetic products markets.

BOTULAX® vs BOTOX® – Active Substance and INN Distinction

The BOTULAX® vs BOTOX® question usually arises because “Botox” has become shorthand for botulinum toxin injections generally. In pharmaceutical terms, the two are separate products. BOTULAX® contains letibotulinumtoxinA; BOTOX® from AbbVie/Allergan contains onabotulinumtoxinA. Both belong to the botulinum toxin type A family, but each has a distinct International Nonproprietary Name (INN), a distinct manufacturing pathway, and its own potency assay.

Because potency measurement is manufacturer-specific and each product has its own reference standard, a unit of BOTULAX® is not automatically equivalent to a unit of BOTOX®. Published protocols cannot be transferred between brands without adjustment, particularly when a clinic is transitioning from one BTX-A formulation to another. Head-to-head trials in aesthetic indications remain limited, though comparative data does exist in therapeutic settings such as post-stroke spasticity, where letibotulinumtoxinA and onabotulinumtoxinA have shown comparable efficacy and safety in Phase 3 evaluation.[2]

The wider commercial subcategory of BTX-A includes at least five distinct INNs in international use:

• OnabotulinumtoxinA
• AbobotulinumtoxinA
• IncobotulinumtoxinA
• PrabotulinumtoxinA
• LetibotulinumtoxinA

Each is a separate purified botulinum toxin with its own regulatory record and clinical evidence base. For clinics planning to buy botulinum toxins more broadly, or those looking specifically to buy Korean botox, understanding the INN distinction is a starting point for product selection, not a technicality.

BOTULAX® Product Range – Vial Sizes and Clinical Applications

Four vial sizes give clinics flexibility to match inventory to caseload and treatment mix.

BOTULAX® 50U

The BOTULAX® 50 vial suits precision work: fine periorbital lines, small correction points, and cases where a clinic wants to minimize waste from partially used vials.

BOTULAX® 100U

The BOTULAX® 100 units vial is the workhorse of general aesthetic practice, and most published dosing guidance for individual treatment areas assumes this concentration. Clinics running a standard mix of upper-face and lower-face treatments typically order this size.

BOTULAX® 200U

For higher-volume clinics, the BOTULAX® 200 vial covers multiple standard treatments from a single reconstitution or supports combined-area sessions where cumulative dosing rises quickly.

BOTULAX® 300U

The BOTULAX® 300 presentation is intended for higher-dose protocols. Hyperhidrosis, full-face treatment plans, and select therapeutic indications where regional approval applies all fall into this range. Comprehensive product details and usage guidance are in the manufacturer’s IFU for each strength.

Reconstitution, Dosage, and Administration

BOTULAX® 100 reconstitution follows the manufacturer’s protocol: add 2.5 to 5 mL of preservative-free sterile 0.9% saline to the vial, then gently rotate until the powder fully dissolves. Avoid vigorous shaking because mechanical stress can denature the toxin protein. At 2.5 mL, the resulting concentration is approximately 4 U per 0.1 mL; at 5 mL, roughly 2 U per 0.1 mL.[4]

Per the manufacturer and the corresponding LETYBO® labeling, once mixed, the reconstituted product should be kept refrigerated at 2°C to 8°C and used within 24 hours.[4]

BOTULAX® post-treatment precautions are standard across the BTX-A class and support consistent outcomes for wrinkle reduction injections:

• No rubbing or massaging the injection sites
• Remain upright for approximately 4 hours
• Avoid strenuous exercise for 24 hours
• Avoid saunas, hot tubs, and prolonged heat exposure the same day
• Limit alcohol on the day of treatment where the treating clinician advises it

Treatment and Clinical Indications

Approved indications vary by market, so practitioners should apply the product label that governs their jurisdiction. In medical aesthetic practice, BOTULAX® is used across several regions of the face and body:

• Upper face (CE-marked cosmetic use): Glabellar lines, horizontal forehead lines, crow’s feet
• Lower face and neck: Masseter reduction, lip flip, chin dimpling, platysmal bands
• Body: Axillary, palmar, or plantar hyperhidrosis using higher-strength vials
• Therapeutic: Cervical dystonia, blepharospasm, and spasticity, subject to local approval. Phase 3 evidence for BOTULAX® in post-stroke upper-limb spasticity has demonstrated efficacy and safety comparable to onabotulinumtoxinA[2]

Combining BOTULAX® with dermal fillers is a standard element of comprehensive facial rejuvenation. BOTULAX® reduces movement-related lines by relaxing the underlying muscle, whereas dermal fillers add volume and soften static contours.

Onset, Duration, and Clinical Performance

Most patients notice the first effect within about 3 days of injection, with the full outcome typically visible by day 10 to 14 as chemodenervation completes at the neuromuscular junction. Phase 3 evidence for letibotulinumtoxinA in moderate-to-severe glabellar lines reports median onset within about 3 days, with a subset of patients responding within 24 hours.[1][5] Duration in aesthetic use generally runs about 4 months, and a proportion of patients report visible benefit extending toward 6 months in the pivotal trials.[1][5]

No published head-to-head randomized controlled trial directly compares BOTULAX® with BOTOX® in aesthetic indications. The most relevant comparative evidence sits in therapeutic use, where a Phase 3 spasticity trial found letibotulinumtoxinA broadly equivalent to onabotulinumtoxinA on efficacy and safety endpoints.[2] BOTULAX® reviews before and after should therefore be interpreted alongside the underlying trial data rather than as substitutes for it.

Regulatory Status – Where Clinics Can and Cannot Buy BOTULAX®

BOTULAX® carries CE marking across the EU and UK and MFDS approval in South Korea. It is not FDA-approved and is not authorized for sale in the United States. Any question about where to buy BOTULAX® must start with that jurisdictional map.

Hugel’s FDA-approved product for the US market is a distinct brand of the same underlying toxin: LETYBO® (letibotulinumtoxinA-wlbg), approved on February 29, 2024, for moderate to severe glabellar lines.[3] Practitioners planning to order BOTULAX® should confirm what their national regulator permits, since prescription-only status applies globally.

Storage and Cold-Chain Requirements

Proper BOTULAX® storage is essential to product performance. Unopened vials require refrigeration at 2°C to 8°C, protection from light, and their original packaging, and should never be frozen. Once reconstituted, the product should remain refrigerated and be used within 24 hours per the manufacturer’s specifications and the corresponding LETYBO® label.[4]

Cold-chain integrity during shipping matters just as much. On receipt, clinics should verify:

• Transport temperature record
• Vial expiration date
• Batch and LOT number against paperwork
• Packaging seal and physical integrity
• Included regulatory documentation

BOTULAX® Price — What Practitioners Should Know Before They Buy BOTULAX® Wholesale

The BOTULAX® price is not fixed. It scales with vial strength, order volume, distribution channel, destination market, and shipping requirements. As a South Korean-manufactured neurotoxin, BOTULAX® for sale internationally tends to be priced competitively against Western BTX-A brands, and larger vials, particularly the 200U and 300U, generally bring the effective cost per unit down for practices that use full vials without waste.

Headline vial prices across brands can be misleading, because dilution ratios, standard treatment dosing, and unit-to-unit potency differ. A more useful figure is the cost per treatment area or per typical patient visit, calculated on the specific dilution and dosing the clinic actually uses. Clinics that buy BOTULAX® wholesale should also factor cold-chain shipping costs, insurance, and expected wastage into any per-unit calculation.

Doctor Medica’s staff can share information on documentation and licensing requirements when a clinic is preparing to order BOTULAX® wholesale through an authorized channel.

BOTULAX® Compared to Other Botulinum Toxin Brands

Vs NABOTA®

Both are South Korean BTX-A products, but they carry different INNs from different manufacturers. BOTULAX® contains letibotulinumtoxinA (Hugel); NABOTA® contains prabotulinumtoxinA (Daewoong Pharmaceutical). The regulatory footprint also diverges sharply. NABOTA® is licensed in the US as Jeuveau® by Evolus and was FDA-approved in February 2019 for glabellar lines, whereas BOTULAX® has no FDA authorization. Where both are CE-marked, clinics generally treat unit dosing as broadly comparable in day-to-day practice, but that comparability rests on clinical convention rather than any formal cross-INN validation. Selection between the two often comes down to per-market regulatory permissions, supplier reliability, and pricing.

Vs INNOTOX®

INNOTOX®, from Medytox, is the distinguishing product in the Korean BTX-A field because it is supplied as a pre-mixed liquid rather than a lyophilized powder. There is no on-site reconstitution step, which some clinics view as a workflow advantage and others as a storage sensitivity, since the liquid formulation is particularly vulnerable to freezing. INNOTOX® contains botulinum toxin type A supplied in a liquid formulation, while BOTULAX® contains letibotulinumtoxinA as a lyophilized powder. The two are separate products from separate manufacturers (Medytox and Hugel, respectively). Both are CE-marked; neither is FDA-approved for aesthetic use in the United States. Practitioners weighing the two typically consider preparation convenience against the temperature tolerances their clinic can guarantee.

Vs LIZTOX®

Both LIZTOX® and BOTULAX® are lyophilized Korean BTX-A products, both are CE-marked, and both require standard saline reconstitution. LIZTOX® has picked up traction in European markets as a cost-competitive option. There is no published head-to-head randomized controlled trial between the two, so any comparative claim has to reference individual product data rather than a direct study. Decisions between them tend to rest on price, distributor availability, and regional regulatory status. LIZTOX

Vs LETYBO®

Both products are based on Hugel’s letibotulinumtoxinA, derived from the same underlying strain. The difference is in their regulatory pathways: the US product carries the specific designation letibotulinumtoxinA-wlbg under its FDA approval, while BOTULAX® is marketed under CE and MFDS approvals for international and Korean markets. LETYBO® received US approval on February 29, 2024, for moderate to severe glabellar lines, backed by the three-trial BLESS program enrolling approximately 1,271 patients.[3][4] BOTULAX® has no FDA authorization. Hugel’s US trial data for LETYBO® positions its 20U dose as comparable to 20U of BOTOX®, but that positioning belongs to the LETYBO® brand within the US regulatory context.

Clinics operating in the US market should treat LETYBO® as Hugel’s authorized product and BOTULAX® as unauthorized for that market, even though both trace back to the same Hugel letibotulinumtoxinA lineage.

Vs XEOMIN®

XEOMIN®’s most cited differentiator is formulation: incobotulinumtoxinA is a “naked” toxin, with the complexing proteins present in most other BTX-A products (BOTULAX® included) removed during purification. The clinical significance of that difference for long-term immunogenicity remains debated rather than settled. XEOMIN® also permits room-temperature storage up to 25°C before reconstitution, whereas BOTULAX® requires refrigeration at 2°C to 8°C throughout its shelf life. XEOMIN® is both FDA-approved and CE-marked and typically commands a price premium over Korean-manufactured BTX-A products. XEOMIN

Clinical Benefits of BOTULAX®

For clinics evaluating BOTULAX® within the broader Korean medical aesthetic products segment, the case tends to rest on a few practical features rather than any single differentiator:

• Four vial strengths (50U, 100U, 200U, 300U) supporting varied treatment volumes
• Manufacturing in South Korea under MFDS oversight and reported >99% purification
• CE marking across the EU, UK, and several additional international markets
• Established international distribution as a leading botulinum toxin brand in Hugel’s portfolio
• Cost positioning that is generally competitive versus Western BTX-A brands
• A growing peer-reviewed evidence base for letibotulinumtoxinA across aesthetic and therapeutic indications[1][5]

Side Effects and Safety

Common adverse effects are typical of the BTX-A class and are generally mild and transient. Headache was the most frequently reported adverse event in the Phase 3 glabellar lines program for letibotulinumtoxinA.[1] Reported reactions include:

• Bruising at the injection site
• Injection-site pain or tenderness
• Localized swelling or redness
• Headache

Indication-specific reactions depend on treatment area. Upper-face injections carry a risk of ptosis or brow asymmetry; neck injections carry a small risk of dysphagia. As with every botulinum toxin type A product, distant spread of toxin effect is a rare but serious class-wide risk carried as a boxed warning on the corresponding US label for LETYBO®, and requires prompt medical assessment when suspected.[4] Comparative Phase 3 evaluation in post-stroke spasticity found no meaningful safety divergence between letibotulinumtoxinA and onabotulinumtoxinA.[2]

Contraindications include known hypersensitivity to botulinum toxin type A or formulation excipients, active infection at the injection site, neuromuscular disorders such as myasthenia gravis, and pregnancy or breastfeeding unless the clinical benefit clearly outweighs the risk under local prescribing guidance.[4]

How to Find Information on Sourcing BOTULAX®

BOTULAX® is restricted to licensed medical professionals and moves through authorized distribution rather than open retail. Practitioners researching where to buy BOTULAX® online typically start with distributor credentials and cold-chain documentation, since those variables affect the product that actually arrives at the clinic more than headline price does. A reliable BOTULAX® supplier should confirm cold-chain handling from origin to delivery, match LOT numbers to a certificate of authenticity, and provide evidence of current licensing to distribute prescription pharmaceuticals in the destination market.

Clinics ordering larger quantities when they buy BOTULAX® wholesale should also verify local import rules and temperature documentation for the full transit path. Requirements to purchase BOTULAX® online vary by jurisdiction, and licensed professionals should confirm what regional regulations permit before placing an order.

Where clinics want to buy BOTULAX® products through a documented channel, Doctor Medica’s staff can share information on distributor requirements and the paperwork typically requested when ordering BOTULAX® online.

Frequently Asked Questions

What is BOTULAX®?

Manufactured by Hugel Inc. in South Korea, BOTULAX® is a letibotulinumtoxinA product supplied as a lyophilized powder in 50U, 100U, 200U, and 300U vials. It carries CE marking for international markets and MFDS approval domestically, and is intended for use by licensed medical professionals only.

Is BOTULAX® the same as BOTOX®?

They are separate pharmaceutical products with different INNs. BOTULAX® contains letibotulinumtoxinA and is made by Hugel; BOTOX® contains onabotulinumtoxinA and is made by AbbVie/Allergan. Because potency units are manufacturer-specific, they are not interchangeable dose-for-dose in clinical use.

What vial sizes does BOTULAX® come in?

Four: 50U for precision work, 100U for standard aesthetic practice, 200U for higher-volume caseloads, and 300U for hyperhidrosis and larger therapeutic protocols. Clinics most commonly order the 100U vial.

How is BOTULAX® reconstituted?

Add preservative-free sterile 0.9% saline to the 100U vial, typically 2.5 mL (yielding ~4U per 0.1 mL) or 5 mL (yielding ~2U per 0.1 mL), using gentle rotation rather than shaking. Refrigerate the reconstituted product and use within 24 hours.[4]

How long do BOTULAX® results last?

First effects usually appear within about 3 days and peak between day 10 and day 14. Aesthetic duration is typically around 4 months in pivotal Phase 3 data, with a proportion of patients seeing benefit extend up to 6 months depending on dose, treatment area, and individual response.[1][5]

Is BOTULAX® FDA approved?

It is not. BOTULAX® holds CE marking and MFDS approval but has never received FDA clearance. Hugel’s FDA-approved brand for the United States is LETYBO® (letibotulinumtoxinA-wlbg), approved on February 29, 2024, for moderate to severe glabellar lines.[3]

Can BOTULAX® be combined with dermal fillers?

It is combined regularly in comprehensive facial rejuvenation planning, since the two product classes address different concerns: BOTULAX® targets dynamic wrinkles from muscle activity, while fillers address volume loss and static folds. Standard post-treatment precautions apply for the toxin portion of the plan.

Where can practitioners find sourcing information for BOTULAX®?

Through authorized distribution channels only, since the product is prescription-only worldwide. Before purchasing, clinics should verify supplier licensing, cold-chain compliance for transit, and complete documentation including LOT numbers and certificates of authenticity.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Citations and Resources

[1] Gold, Michael et al. “Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Moderate and Severe Glabellar Lines in Females 35 to 50 Years of Age: Post Hoc Analyses of the Phase 3 Clinical Study Data.” Aesthetic surgery journal. Open forum vol. 6 ojae010. 23 Feb. 2024, doi:10.1093/asjof/ojae010

[2] Do, Kyung Hee et al. “Safety and efficacy of letibotulinumtoxinA(BOTULAX®) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial.” Clinical rehabilitation vol. 31,9 (2017): 1179-1188. doi:10.1177/0269215516689331

[3] U.S. Food and Drug Administration. “Drug Trials Snapshots: Letybo.” U.S. Food and Drug Administration, www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-letybo.

[4] U.S. Food and Drug Administration. LETYBO (LetibotulinumtoxinA-wlbg) Injection: Prescribing Information. Revised Feb. 2024, U.S. Food and Drug Administration, www.accessdata.fda.gov/drugsatfda_docs/label/2024/761225s000lbl.pdf.

[5] Mueller, Daniel S et al. “Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study.” Aesthetic surgery journal vol. 42,6 (2022): 677-688. doi:10.1093/asj/sjac019

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.

Doctor Medica sources products exclusively through authorized distributors and established procurement channels. Products are verified as genuine, and supplied in the original packaging with their seal intact. Learn more about how we guarantee product authenticity, sourcing compliance, and traceable delivery to our clients.